Latest Biotech News

Roche released phase‑3 results showing its BTK inhibitor fenebrutinib achieved non‑inferiority versus Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (PPMS), cutting the risk of...

A study published in Nature Communications reported an association between the recombinant zoster vaccine (RZV) and a statistically significant reduction in dementia risk. Researchers analyzed...

MD Anderson reported first‑in‑human data for RB‑1355, an engineered immune cell therapy tested in relapsed or refractory non‑Hodgkin lymphoma. The initial study showed acceptable safety and...

Medable rolled out an Agentic AI product designed to support principal investigators in assessing electronic clinical outcome assessment data. The tool automates reconciliation tasks, surfaces...

Takeda signed a multiyear R&D collaboration with San Diego AI biotech Iambic to apply generative and predictive models to small‑molecule programs across oncology, gastrointestinal, and...

QuantX Biosciences raised $85 million in a Series B led by Lilly and Sanofi Ventures to advance its China‑American pipeline focused on popular immunology targets. The financing will support R&D,...

Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to secure the company’s circular RNA platform for in vivo CAR‑T therapies. Lilly said Orna’s lead program, ORN‑252, a...

Medable launched an "Agentic AI" product designed to help principal investigators (PIs) manage and assess electronic clinical outcome assessment (eCOA) data. The company says the agent is...

FDA Commissioner Marty Makary pledged swift enforcement against companies mass‑marketing unapproved copycat drugs after telehealth firm Hims announced a compounded semaglutide pill claimed to...

Waters Corporation closed its $18.8 billion transaction to combine with Becton Dickinson’s Biosciences & Diagnostic Solutions business, but reported that the acquired unit missed Q4 revenue...

Takeda signed a multiyear collaboration with San Diego AI biotech Iambic to apply generative AI for small‑molecule discovery across oncology, gastrointestinal and inflammation targets. The...

Roche presented phase 3 data showing its BTK inhibitor fenebrutinib reduced the risk of disability progression by 12% versus Ocrevus in primary progressive multiple sclerosis (PPMS), meeting...

Aerska Therapeutics secured $39 million in follow‑on financing to advance its brain‑shuttle platform that ferries siRNA past the blood‑brain barrier by hitching payloads to antibodies mimicking...

Eli Lilly expanded its long‑standing relationship with Innovent Biologics through a new collaboration focused on oncology and immunology programs, featuring $350 million in upfront payments and...

The United Arab Emirates announced a partnership with Colossal Biosciences to establish the Colossal BioVault and World Preservation Lab at Dubai’s Museum of the Future, a nine‑figure initiative...

Roivant Sciences’ Priovant Therapeutics reported that brepocitinib, a dual JAK1/TYK2 inhibitor licensed from Pfizer, met proof‑of‑concept goals in cutaneous sarcoidosis — a rare inflammatory skin...

Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to add an in‑vivo CAR‑T platform built on engineered circular RNA and lipid nanoparticle delivery. Orna’s lead program,...

Roche disclosed phase 3 results showing its BTK inhibitor fenebrutinib was non‑inferior to Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (PPMS), reducing the risk of confirmed...

Takeda signed a multiyear R&D partnership with San Diego‑based Iambic to accelerate small‑molecule discovery across oncology, gastrointestinal and inflammation targets. The collaboration will...

Novo Nordisk filed suit against telehealth company Hims & Hers alleging infringement of semaglutide (Wegovy) patents, and signaled it may seek 'hundreds of millions' in damages. The complaint...